BI 1569912 Phase 1 Results: GluN2B NAM Safety in Germany & Japan

BI 1569912 Demonstrates Favorable Safety and Tolerability in Phase 1 Trials

Three partially randomized, placebo-controlled phase 1 trials conducted in Germany and Japan found that BI 1569912, an orally administered GluN2B-selective negative allosteric modulator (NAM) of the N-methyl-D-aspartate (NMDA) receptor, was safe and well-tolerated in healthy adults. Across single and multiple rising dose studies (ClinicalTrials.gov: NCT04445090, NCT04978506, NCT04958252), no deaths, serious adverse events (AEs), or discontinuations due to AEs were reported. Importantly, there was no clinical evidence of dissociation or altered states, a key distinction from classic psychedelics.

Mechanism: GluN2B-Selective NAMs and Their Distinction from Psychedelics

BI 1569912 acts as a negative allosteric modulator at the GluN2B subunit of the NMDA receptor, a target implicated in neuropsychiatric disorders such as depression and chronic pain. Unlike classic psychedelics, which primarily act on serotonin 5-HT2A receptors and induce altered states of consciousness, GluN2B-selective NAMs do not produce perceptual or dissociative effects at therapeutic doses. This pharmacological profile addresses a growing interest in non-hallucinogenic central nervous system (CNS) therapeutics that may offer efficacy without the regulatory and clinical complexities of psychedelic experiences.

In these trials, BI 1569912 was rapidly absorbed and eliminated, with dose-proportional increases in plasma exposure. The pharmacokinetic (PK) profile was consistent across oral solution and tablet formulations, and steady state was achieved by Day 3 of multiple dosing. Food and evening dosing reduced peak plasma concentration (Cmax) but did not alter overall drug exposure (AUC), a nuanced finding that may inform dosing strategies in future studies.

Policy, Research, and Industry Implications

The demonstration of safety and tolerability for BI 1569912 in both young and elderly healthy adults, across European and Asian populations, provides a solid foundation for advancing this compound into phase 2 trials targeting neuropsychiatric indications. The lack of dissociation or abuse liability signals distinguishes BI 1569912 from ketamine and other NMDA antagonists, which are tightly regulated due to their psychoactive properties.

• For researchers, these results open avenues to explore GluN2B-selective modulation as a therapeutic mechanism in depression, anxiety, and chronic pain without the confounding effects of altered states.
• For policymakers and regulators, the absence of classic psychedelic effects may streamline clinical development and reduce barriers to approval, as risk profiles differ substantially from Schedule I substances.
• For industry, the favorable PK and safety data across age groups and ethnicities support broader patient inclusion in subsequent trials, potentially accelerating development timelines and market entry.

One non-obvious implication is that the clear separation between CNS efficacy and psychoactivity in BI 1569912 could shift investment and clinical trial design strategies away from compounds requiring intensive psychotherapy or specialized clinical infrastructure, as seen in psychedelic-assisted therapy models.

Risks, Unknowns, and Failure Modes

While phase 1 results are promising, the absence of serious adverse events and dissociation in healthy volunteers does not guarantee efficacy or safety in patient populations with neuropsychiatric disorders. The trials did not assess therapeutic endpoints, and the long-term effects of GluN2B modulation remain unknown. Additionally, the reduction in Cmax with food or evening dosing, though not affecting AUC, may have clinical relevance if peak plasma levels are linked to efficacy or side effects in future studies.

A real-world failure mode for NMDA receptor modulators is the potential for subtle cognitive or mood effects that only emerge in vulnerable populations or with chronic administration. Furthermore, while the lack of dissociation is a regulatory advantage, it may limit rapid-onset efficacy seen with agents like ketamine, which remains an open question for this drug class.

Looking Forward: Next Steps for BI 1569912 and the CNS Field

The positive phase 1 data for BI 1569912 set the stage for phase 2 studies in patients with depression, anxiety, or pain disorders, where efficacy and longer-term safety will be critically evaluated. The compound’s clear safety profile and lack of psychoactivity may catalyze a broader shift in CNS drug development toward non-hallucinogenic mechanisms, appealing to both regulators and clinicians. However, the ultimate clinical value of GluN2B-selective NAMs will depend on their ability to deliver meaningful symptom relief in target populations without unforeseen adverse effects.

For the psychedelic medicine field, BI 1569912 exemplifies a parallel innovation track: leveraging neuroplasticity and NMDA modulation without the complexities of altered states. As more data emerge, the field will need to balance enthusiasm for novel mechanisms with rigorous assessment of real-world impact and safety.

How we research: This article was researched and written by Dr. Alex Harper, PhD (Neuroscience), reviewed by Dr. Miriam Lee, MD (Psychiatry) on 2026-09-04. Primary sources include trial registrations and the original OpenAlex publication (W7205008081).